Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway

Abstract

Background

Survival time among patients with multiple sclerosis (MS) has varied considerably according to previous reports.

Objectives

Survival and cause of death were analyzed among all patients with MS (878) with onset of MS in Hordaland County, Western Norway during 1953–2003, of whom 198 were dead at follow-up on January 1, 2005.

Methods

Standardized mortality ratios (SMRs) and relative mortality ratios (RMRs) were calculated based on observed mortality in MS and expected mortality.

Results

Median survival from onset was 41 years versus 49 years in the corresponding population, and mortality (SMR) was 2.7-fold increased in MS. The median survival was 43 years among women and 36 years among men, but women had higher relative mortality, when compared with the corresponding population, than men (RMR = 1.40). The median survival time was 45 years among young-onset patients (21–30 years) and 23 years among older-onset patients (51–60 years), but young-onset patients had higher relative mortality than older-onset patients, as shown by a significant reduction by 10-year interval of age at onset (RMR = 0.65). Median survival from onset was longer (43 years) among relapsing–remitting MS than primary progressive MS ([PPMS]; 49 years), and the relative mortality was higher in the PPMS group, (RMR = 1.55). According to death certificates, 57% died from MS.

Conclusion

Female patients and patients with young onset had longer median time to death but higher relative risk of dying compared with the corresponding population. PPMS had both shorter median time to death from onset and a higher relative risk of dying.

Keywords

Get full access to this article

View all access options for this article.

References

1 Riise T Grønning M Aarli JA Nyland H Larsen JP Edland A . Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988; 41: 1031–1036.

2 Confavreux C Aimard G Devic M . Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281–300.

3 Brønnum-Hansen H Koch-Henriksen N Stenager E . Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127: 844–850.

4 Cottrell DA Kremenchutzky M Rice GPA . The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625–639.

5 Wallin MT; Page WF; Kurtzke JF; . Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000; 123: 1677–1687.

6 Sumelathi M-L Tienari PJ Wikström J Salminen TM Hakama M . Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8: 350–355.

7 Malmgren RM Valdiviezo NL Visscher BR . Underlying cause of death as recorded for multiple sclerosis patients: associated factors. J Chronic Dis 1983; 36: 699–705.

8 Larsen JP Kvale G Aarlie JA . Multiple sclerosis and mortality statistics. Acta Neurol Scand 1985; 71: 237–241.

9 Phadke JG . Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987; 50: 523–531.

10.

10 Sadovnick AD Eisen RN Ebers GC Paty DW . Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193–1196.

11.

11 Stenager EN Stenager E Koch-Henriksen N . Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992; 55: 542–545.

12.

12 Midgard R Albrektsen G Riise T Kvale G Nyland H . Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995; 58: 417–421.

13.

13 Koch-Henriksen N Brønnum-Hansen H Stenager E . Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998; 65: 56–59.

14.

14 Pekmezovic T Jarebinski M Drulovic J Stojsavlevic N Levic Z . Survival of multiple sclerosis patients in the Belgrade population. Neuroepidemiology 2002; 21: 235–240.

15.

15 Weinschenker BG . The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119–146.

16.

16 Ebers GC . Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252(Suppl. 3): iii15–iii20.

17.

17 Presthus J . Report on the multiple sclerosis investigations in west-Norway. Acta Neurol Scand 1960; 147(Suppl.): 88–92.

18.

18 Larsen JP Aarli JA Nyland H Riise T . Western Norway, a high-risk area for multiple sclerosis: a prevalence/incidence study in the county of Hordaland. Neurology 1984; 34: 1202–1207.

19.

19 Grønning M Riise T Kvåle G Nyland H Larsen JP Aarli JA . Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. Neuroepidemiology 1991; 10: 53–61.

20.

20 Riise T Grønning M Aarli JA Nyland H Larsen JP Edland A . Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988; 41: 1031–1036.

21.

21 Myhr KM Grytten N Aarseth JH Nyland H . The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis registry—a resource for clinical practice and research. Acta Neurol Scand 2006; 183(Suppl.): 37–40.

22.

22 Grytten N Glad S Aarseth J Nyland H Midgard R Myhr KM . A 50 year follow-up of the incidence of multiple sclerosis in Hordaland County, western Norway. Neurology 2006; 66: 182–186.

23.

23 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 14: 227–231.

24.

24 Lie SA Lie RT Svanes C . Expected survival compared with survival of peptic ulcer patients. Stat Med 1998; 17: 1189–1199.

25.

25 Andersen PK Væth M . Simple parametric and nonparametric models for excess and relative mortality. Biometrics 1989; 45: 523–535.

26.

26 Andersen PK Borch-Johnsen K Deckert T . A Cox regression model for the relative mortality and its application to diabetes mellitus survival data. Biometrics 1985; 41: 921–932.

27.

27 Broman T Andersen O Bergmann L . Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 1981; 63: 6–33.

28.

28 Runmarker B Andersen O . Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117–134.

29.

29 Eriksson M Andersen O Runmarker B . Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2003; 9: 260–274. Erratum: Mult Scler 2003; 9: 641.

30.

30 Weinshenker BG Bass B Rice GPA . The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133–146.

31.

31 Weinshenker BG Bass B Rice GPA . The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419–1428.

32.

32 Wynn DR Rodriguez M O’Fallon WM Kurland LT . A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780–786.

33.

33 Leray E Morrisey SP Yaouang J . Long-term survival of patients with multiple sclerosis in West France. Mult Scler 2007; 13: 865–874.

34.

34 Confavreux C Vukusic S . Age at disability milestones in multiple sclerosis. Brain 2006; 129: 595–605.

35.

35 Tremlett H Paty D Devonshire V . Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172–177.

36.

36 Hughes GRV . Lupus patients are protected from cancer. Lupus 2001; 10: 833–834.

37.

37 Percy AK Nobrega FT Okazaki H Glattre E Hurland T . Multiple sclerosis in Rochester, Minn. A 60-year appraisal. Arch Neurol 1971; 25: 105–111.

38.

38 Palo J Duchesne J Wikstrom J . Malignant diseases among patients with multiple sclerosis. J Neurol 1977; 216: 217–222.

39.

39 Moller H Keller RW Boice JD Olsen JH . Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 1991; 84: 214–220.

40.

40 Midgard R Glattre E Gronning M Riise T Edland A Nyland H . Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996; 93: 411–415.

41.

41 Achiron A Barak Y Gail M . Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005; 89: 265–270.

42.

42 Ledda A Caocci G Spinicci G Cocco E Mmusa E Nasa GL . Two new cases of acute promyelocytic leukaemia following mitoxantrone treatment in patients with multiple sclerosis. Leukaemia 2006; 20: 2217–2218.